

2 (i) an antineoplastic alkylphospholipid,
3 (ii) an antineoplastic water -or lipid-soluble antiestrogen associated in
4 liposomal form with said antineoplastic alkylphospholipid,
5 (iii) a nonneoplastic phospholipid, and
6 optionally one or more of (iv) a sterol, (v) a positively or negatively
7 charged lipid, and (vi) a PEG lipid.--

1 *AR*
2 -- 11. The composition of claim 10, wherein said alkylphospholipid has the
3 formula

Sub
B1
CDT
4 R-Y-P-X
5 wherein
6

7 R is a C₁₂₋₂₂ alkyl, alkenyl, or alkinyl residue,
8 Y is oxygen, sulfur, or a CH₂ residue,
9 P is a PO₂ residue, and
X is a choline, or modified choline residue, or serine, ethanolamine, or
glycerine group, or a synthetic modification thereof. --

1 -- 12. The composition of claim 10, wherein said alkylphospholipid is
2 hexadecylphosphocholine, octadecylphosphocholine, erucylphosphocholine,
3 octadecyl-[2-(N-methylpiperidino)ethyl]phosphate,

4 octadecylphosphoethanolamine, or hexadecyl-phosphoserine.--

1 -- 13. The composition of claim 10, wherein said antiestrogen is tamoxifen,
2 droloxifen, toremifene, idoxiphen, raloxiphen, miproxiphen-phosphate (TAT-59),
3 ICI 164,3384, ICI 182,780, a main metabolite of tamoxiphen, 4-hydroxy tamoxi-
phen, N-desmethyltamoxiphen.--

*Sub
B7
C054
A2*
1 -- 14. The composition of claim 10, wherein said nonneoplastic

2 phospholipid is a naturally occurring or synthetic material, with a lipid :
3 antiestrogen molar ratio of between 0-10 : 1 (m/m). --

1 -- 15. The composition of claim 14, wherein said nonneoplastic
2 phospholipid is phosphocholine, serine, ethanolamine, glycerol.--

1 -- 16. The composition of claim 10, wherein said sterol is cholesterol, or
2 sitosterol in a sterol : alkylphospholipid molar ratio of 0-1 : 1.--

1 -- 17. The composition of claim 10, wherein said PEG lipid is N-(O-
2 methoxy-polyethyleneglycyl)-1,2-distearyl-s,n-glycero-3-phosphoethanolamine
3 (PEG₂₀₀₀ -